Sana Biotechnology, Inc. 8-K

What Happened

• On April 10, 2026 Sana Biotechnology (SANA) entered a Stock Purchase Agreement with Mayo Clinic to sell 7,507,507 shares of common stock at $3.33 per share (gross proceeds ≈ $25.0M). Mayo Clinic can elect on or before August 31, 2026 to purchase an additional 7,507,507 shares at the same price (another ≈ $25.0M).
• The Initial Shares are expected to close on or about April 15, 2026. If Mayo Clinic makes the Election, closing for the Additional Shares is expected 10–20 business days after Mayo Clinic delivers the Election, subject to customary closing conditions.
• The shares are being offered under Sana’s effective Form S-3 shelf (Reg. No. 333-293981). Sana expects net proceeds from the Initial Shares of approximately $24.9M and intends to use proceeds to develop products covered by a related license with a Mayo Clinic affiliate, including SC451 and certain genetically modified stem‑cell derived islet cell products.

Key Details

• Shares and price: 7,507,507 Initial Shares at $3.33/share; option for additional 7,507,507 shares at same price.
• Proceeds: Gross ≈ $25.0M (Initial), anticipated net ≈ $24.9M; potential additional gross ≈ $25.0M if option exercised.
• Timing and conditions: Initial close ≈ April 15, 2026; Additional close 10–20 business days after Election (if made by Aug 31, 2026); closings subject to customary conditions.
• Sale restrictions: Mayo Clinic agreed not to sell or transfer the securities until the later of (i) six months after the Initial Shares closing, and (ii) if the Additional Shares are purchased, three months after that closing.
• Cash runway: Sana had $138.4M cash as of Dec 31, 2025; combined with expected net proceeds from the Initial Shares, the company says this is expected to fund operations into 2027.

Why It Matters

• The transaction provides near‑term non‑dilutive financing from a strategic healthcare partner (≈ $25M now, with potential for $25M more), strengthening Sana’s cash position and extending its funding runway into 2027 per the company.
• Proceeds are earmarked for development of programs tied to a Mayo Clinic affiliate under a separate license—this links part of Sana’s R&D funding to a partner that may have royalty rights on those products.
• Investors should note potential dilution from the new share issuance and the additional optional tranche, the resale restrictions on Mayo Clinic’s shares, and that closings are subject to customary conditions. The filing also includes standard forward‑looking statement caution.